225 related articles for article (PubMed ID: 37049787)
21. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
22. A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting Leukemia.
Ozyerli-Goknar E; Nizamuddin S; Timmers HTM
ChemMedChem; 2021 May; 16(9):1391-1402. PubMed ID: 33534953
[TBL] [Abstract][Full Text] [Related]
23. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias.
Grembecka J; Belcher AM; Hartley T; Cierpicki T
J Biol Chem; 2010 Dec; 285(52):40690-8. PubMed ID: 20961854
[TBL] [Abstract][Full Text] [Related]
25. Design and synthesis of benzylpiperidine inhibitors targeting the menin-MLL1 interface.
Ren J; Xu W; Tang L; Su M; Chen D; Chen YL; Zang Y; Li J; Shen J; Zhou Y; Xiong B
Bioorg Med Chem Lett; 2016 Sep; 26(18):4472-4476. PubMed ID: 27528435
[TBL] [Abstract][Full Text] [Related]
26. High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction.
He S; Senter TJ; Pollock J; Han C; Upadhyay SK; Purohit T; Gogliotti RD; Lindsley CW; Cierpicki T; Stauffer SR; Grembecka J
J Med Chem; 2014 Feb; 57(4):1543-56. PubMed ID: 24472025
[TBL] [Abstract][Full Text] [Related]
27. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction.
Zhou H; Liu L; Huang J; Bernard D; Karatas H; Navarro A; Lei M; Wang S
J Med Chem; 2013 Feb; 56(3):1113-23. PubMed ID: 23244744
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological inhibition of the mixed lineage leukemia 1-menin interaction aggravates acute kidney injury induced by folic acid and ischemia-reperfusion in mice.
Hou X; Cui B; Qiu A; Liu N; Zhuang S
Am J Physiol Renal Physiol; 2023 Nov; 325(5):F669-F680. PubMed ID: 37733875
[TBL] [Abstract][Full Text] [Related]
29. Targeting IGF2BP3 enhances antileukemic effects of menin-MLL inhibition in MLL-AF4 leukemia.
Lin TL; Jaiswal AK; Ritter AJ; Reppas J; Tran TM; Neeb ZT; Katzman S; Thaxton ML; Cohen A; Sanford JR; Rao DS
Blood Adv; 2024 Jan; 8(2):261-275. PubMed ID: 38048400
[TBL] [Abstract][Full Text] [Related]
30. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
[TBL] [Abstract][Full Text] [Related]
31. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia.
Kühn MW; Armstrong SA
Cancer Cell; 2015 Apr; 27(4):431-3. PubMed ID: 25873167
[TBL] [Abstract][Full Text] [Related]
32. Challenges and opportunities in targeting the menin-MLL interaction.
Cierpicki T; Grembecka J
Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
[TBL] [Abstract][Full Text] [Related]
33. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
[TBL] [Abstract][Full Text] [Related]
34. Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).
Fiskus W; Boettcher S; Daver N; Mill CP; Sasaki K; Birdwell CE; Davis JA; Takahashi K; Kadia TM; DiNardo CD; Jin Q; Qi Y; Su X; McGeehan GM; Khoury JD; Ebert BL; Bhalla KN
Blood Cancer J; 2022 Jan; 12(1):5. PubMed ID: 35017466
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Novel, Potent, and Selective Small-Molecule Menin-Mixed Lineage Leukemia Interaction Inhibitors through Attempting Introduction of Hydrophilic Groups.
Lei H; Zhang SQ; Bai H; Zhao HY; Sun J; Chuai H; Xin M
J Med Chem; 2022 Oct; 65(19):13413-13435. PubMed ID: 36173787
[TBL] [Abstract][Full Text] [Related]
36. Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
Svoboda LK; Teh SSK; Sud S; Kerk S; Zebolsky A; Treichel S; Thomas D; Halbrook CJ; Lee HJ; Kremer D; Zhang L; Klossowski S; Bankhead AR; Magnuson B; Ljungman M; Cierpicki T; Grembecka J; Lyssiotis CA; Lawlor ER
J Pathol; 2018 Jul; 245(3):324-336. PubMed ID: 29672864
[TBL] [Abstract][Full Text] [Related]
37. Targeting the undruggable: menin inhibitors ante portas.
Dempke WCM; Desole M; Chiusolo P; Sica S; Schmidt-Hieber M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9451-9459. PubMed ID: 37103568
[TBL] [Abstract][Full Text] [Related]
38. MLL1 inhibition reduces IgM levels in Waldenström macroglobulinemia.
Karbalivand M; Almada LL; Ansell SM; Fernandez-Zapico ME; Elsawa SF
Leuk Res; 2022 May; 116():106841. PubMed ID: 35462170
[TBL] [Abstract][Full Text] [Related]
39. A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1.
Numata M; Haginoya N; Shiroishi M; Hirata T; Sato-Otsubo A; Yoshikawa K; Takata Y; Nagase R; Kashimoto Y; Suzuki M; Schulte N; Polier G; Kurimoto A; Tomoe Y; Toyota A; Yoneyama T; Imai E; Watanabe K; Hamada T; Kanada R; Watanabe J; Kagoshima Y; Tokumaru E; Murata K; Baba T; Shinozaki T; Ohtsuka M; Goto K; Karibe T; Deguchi T; Gocho Y; Yoshida M; Tomizawa D; Kato M; Tsutsumi S; Kitagawa M; Abe Y
Cancer Cell Int; 2023 Feb; 23(1):36. PubMed ID: 36841758
[TBL] [Abstract][Full Text] [Related]
40. Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
Brzezinka K; Nevedomskaya E; Lesche R; Haegebarth A; Ter Laak A; Fernández-Montalván AE; Eberspaecher U; Werbeck ND; Moenning U; Siegel S; Haendler B; Eheim AL; Stresemann C
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
